Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 0.62 |
| ▸ | MAP2K2 | P36507 | 10/20 | 0.62 |
| ▸ | PIM1 | P11309 | 1/20 | 0.61 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.61 |
| ▸ | BRAF | P15056 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.61 |
| ▸ | RAF1 | P04049 | 1/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.59 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.59 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.59 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.59 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.59 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4852779 | 1.00 | MAP2K1 (0.62) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL30584462 | 1.00 | MAP2K1 (0.62) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL5989619 | 0.89 | MAP2K1 (0.48) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL5989612 | 0.89 | MAP2K1 (0.48) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL23651905 | 0.89 | MAP2K1 (0.49) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL26249791 | 0.88 | MAP2K1 (0.53) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL24925752 | 0.86 | MAP2K1 (0.52) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL2025095 | 0.86 | MAP2K1 (0.49) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL2025366 | 0.86 | MAP2K1 (0.49) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL29308283 | 0.86 | PIM1 (0.46) | MAP2K1MAP2K2PIM1CAMK2BBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6972298-B2 | Method of treating or inhibiting neutrophil chemotaxis by administering a MEK inhibitor | WARNER-LAMBERT COMPANY (US) | 2005-12-06 | — | — | US | claimed |
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2005-08-11 | — | — | US | claimed |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2004-03-18 | — | — | US | claimed |
| EP-1301472-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2003-04-16 | — | — | EP | claimed |
| US-20030055095-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | BARAGI VIJAYKUMAR M (US) | 2003-03-20 | — | — | US | claimed |
| EP-1262176-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | WARNER-LAMBERT COMPANY (US) | 2002-12-04 | — | — | EP | claimed |
| WO-2002006213-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2002-01-24 | — | — | WO | claimed |
| EP-1301472-B1 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER LAMBERT CO (US) | 2014-03-26 | — | — | EP | disclosed |
| US-7411001-B2 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| WO-2007042885-A2 | THERAPEUTIC COMBINATION COMPRISING METHOTREXATE AND A SPECIFIED INHIBITOR OF MEK1 AND MEK2 | PFIZER PRODUCTS INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| EP-1682495-A1 | POLYMORPHIC FORM OF N- (R)-2,3-DIHYDROXY-PROPOXY -3,4-D IFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)-BENZAMIDE | Warner-Lambert Company LLC (US) | 2006-07-26 | — | — | EP | disclosed |
| US-7060856-B2 | Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | WARNER-LAMBERT COMPANY (US) | 2006-06-13 | — | — | US | disclosed |
| US-6972298-B2 | Method of treating or inhibiting neutrophil chemotaxis by administering a MEK inhibitor | WARNER-LAMBERT COMPANY (US) | 2005-12-06 | — | — | US | disclosed |
| WO-2005040098-A1 | POLYMORPHIC FORM OF N-[(R)-2,3-DIHYDROXY-PROPOXY]-3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)-BENZAMIDE | WARNER-LAMBERT COMPANY LLC (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20050085550-A1 | Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | WARNER-LAMBERT COMPANY | 2005-04-21 | — | — | US | disclosed |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2004-03-18 | — | — | US | disclosed |
| EP-1301472-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20030055095-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | BARAGI VIJAYKUMAR M (US) | 2003-03-20 | — | — | US | disclosed |
| EP-1262176-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | WARNER-LAMBERT COMPANY (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2002006213-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085550-A1 | Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | HLA-DRB1, UGT1A3, BBC3 | MAP2K1 4611/4885MAP2K2 4300/4885PIM1 4150/4885 |
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | CYP4X1, CYP2A7, CYP4B1 | MAP2K1 4341/4885MAP2K2 4268/4885PIM1 1919/4885 |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | CYP4X1, ALOX5, HAAO | MAP2K1 4312/4885MAP2K2 4025/4885PIM1 2425/4885 |
| US-20030055095-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | MMP8, SERPINB1, CXCR2 | MAP2K1 105/4885MAP2K2 89/4885PIM1 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.